Description
The worldwide market for prescription cardiovascular drugs encompasses a wide variety of products that treat the many facets of cardiovascular disease. The field of cardiology is currently experiencing a busy and dynamic period. As a result, the range of therapeutic options available to physicians has expanded significantly in the past few years and the development pipeline promises even more weapons soon. The sheer size and diversity of the current market and the potential of new products make this therapeutic category among the most competitive of prescription drug segments.
This comprehensive market study considers the following market segments:
- Cardiac glycosides and positive inotropic agents
- Antihypertensive agents
- Antiarrhythmic agents
- Vasodilators and peripheral vasodilator agents
- Antihyperlipidemic agents
- Blood modifiers
- Diuretic agents
- Other cardiovascular agents
Specific diseases and disorders discussed include:
- Angina
- Arrhythmia
- Atherosclerosis
- Congestive heart failure
- Coronary artery disease
- Hypertension
- Myocardial infarction
- Other disorders
The report details the various categories of cardiovascular drugs and describes U.S. and non-U.S. markets in each of the specific cardiovascular drug areas. Revenues are considered in each subsegment according to type of drug. In addition, top products in each category are reviewed. The report also covers market drivers and trends that are influencing the market. It further identifies major market factors, which are discussed in detail, and a total market summary is presented.
All market data are presented at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2004. Historical data are provided for 2002 and 2003, and forecast data are provided for each of the years 2005 through 2009. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2004 base year.
The information and analysis presented in this report are based on extensive interviews with senior management of top companies and other participants in the cardiovascular market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 41 industry executives and product managers to validate and obtain expert opinion on current and future trends in the cardiovascular market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
Table of Contents
chapter one: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction
- Overview of the Cardiovascular System
- Heart
- Circulatory System
- Cardiac Cycle
- Coronary Circulation
- Cardiac Myocytes
- Contraction
- Cardiac Energy Metabolism
- Cardiac Output
- Cardiovascular Disorders
- Angina
- Arrhythmias
- Atherosclerosis
- Congestive Heart Failure
- Coronary Artery Disease
- Hypertension
- Myocardial Infarction
- Effects of Aging
- Demographics
- Disease Management
Chapter three: Issues and Trends
- Immediate Statin Use Investigated
- Clinical Trial Image
- Inflammation reduction
- Unique Drug Combinations
- Antihypertensive Blockbuster
- OTC Statins
chapter Four: Prescription Cardiac Glycoside and Iontropic Drugs
- Overview of Cardiac Glycosides and Inotropic Drugs
- Description of Products
- Market Size and Growth
- World Market
- The U.S. Market
- Non-U.S. Market
- Research and Development
- Competitive Analysis
Chapter Five: Prescription Antihypertensive Drugs
- Overview
- Description of Products
- ACE Inhibitors
- Angiotensin II Receptor Antagonists
- Adrenergic Blockers
- Beta Blockers
- Calcium Channel Blockers
- Combinations
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Research and Development
- Competitive Analysis
chapter Six: Prescription Antiarrhythmic Drugs
- Overview
- Description of Products
- Class I
- Class II
- Class III
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Research and Development
- Competitive Analysis
chapter Seven: Prescription Vasodilator and Peripheral Vasodilator Drugs
- Overview
- Description of Products
- Coronary Vasodilators
- Natriuretic Peptides
- Peripheral Vasodilators
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Research and Development
- Competitive Analysis
Chapter Eight: Prescription Antihyperlipidemic Drugs
- Overview
- Description of Products
- Bile Acid Sequestrants
- Fibric Acid Derivatives
- HMG-CoA Reductase Inhibitors (Statins)
- Nicotinic Acid
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Research and Development
- Competitive Analysis
chapter nine: Prescription Blood Modifiers
- Overview
- Description of Products
- Anticoagulants
- Antiplatelets
- Thrombolytics
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Research and Development
- Competitive Analysis
chapter ten: Prescription Diuretic Drugs
- Overview
- Description of Products
- Carbonic Anhydrase Inhibitors
- Loop
- Potassium-Sparing
- Thiazides
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Research and Development
- Competitive Analysis
chapter eleven: Prescription Other Cardiovascular Drugs
- Overview
- Description of Products
- Market Size and Growth
- World Market
- U.S. Market
- Non-U.S. Market
- Research and Development
- Competitive Analysis
Chapter twelve: World Market Summary
- Overview
- Total market Size and Forecast
- Competitive Analysis
Chapter thirteen: Corporate Profiles
- Abbott Laboratories
- Astrazeneca
- Astrazeneca
- Bayer Corporation
- Biovail Corporation
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Genentech, Inc.
- GlaxoSmithKline
- Merck & Company Inc
- Novartis International AG
- Pfizer, Inc.
- Roche
- Sankyo Pharmaceuticals
- Sanofi-Aventis
- Schering-Plough
- Wyeth
Appendix A: Selected Emerging Cardiovascular Company Briefs
- Cardiome Pharma Corporation
- Myogen
- Vasogen
Appendix B: Company Directory
List of Exhibits
chapter one: Executive Summary
- Table 1-1: Total World Prescription Cardiovascular Drug Market 2002-2009
- Figure 1-1: Total World Prescription Cardiovascular Drug Market 2002-2009
- Table 1-2: Top 17 Prescription Cardiovascular Drug Marketers: Cardiovascular Revenues and Segments of Participation 2004
chapter two: Introduction
- Table 2-1: U.S. Prevalence, Incidence and Mortality of Selected Cardiovascular Conditions
chapter four: Prescription Cardiac Glycoside and Iontropic Drugs
- Table 4-1: Currently Marketed Cardiac Glycosides and Inotropic Drugs
- Table 4-2: Total World Market for Cardiac Glycoside and Inotropic Drugs 2002-2009
- Figure 4-1: World Cardiac Glycoside and Inotropic Drug Market 2002-2009
- Table 4-3:Total U.S. Market for Cardiac Glycoside and Inotropic Drugs 2002-2009
- Figure 4-2: Total U.S. Cardiac Glycoside and Inotropic Drug Market 2002-2009
- Table 4-4: Total Non-U.S. Market for Cardiac Glycoside and Inotropic Drugs 2002-2009
- Figure 4-3: Total Non-U.S. Cardiac Glycoside and Inotropic Drug Market 2002-2009
- Table 4-5: Cardiac Glycosides and Inotropic Agents in Development
- Table 4-6: Cardiac Glycoside and Inotropic Drug Revenues and Market Share by Supplier 2004
- Figure 4-4: Total Global Market for Cardiac Glycoside & Inotropic Drugs, Market Share by Leading Supplier 2004
chapter five: Prescription Antihypertensive Drugs
- Table 5-1: Currently Marketed ACE Inhibitors
- Table 5-2: Currently Marketed Angiotensin II Receptor Antagonists
- Table 5-3: Currently Marketed Adrenergic and Beta Blockers
- Table 5-4: Currently Marketed Calcium Channel Blockers
- Table 5-5: Currently Marketed Combination Antihypertensives
- Table 5-6: Total World Market for Prescription Antihypertensive Drugs 2002-2009
- Figure 5-1: Total World Market for Prescription Antihypertensive Drugs 2002-2009
- Table 5-7: World Market for Prescription Antihypertensive Drugs by Type (ACE Inhibitors, Angiotensin II Receptor Antagonists, Adrenergic Blockers, Beta Blockers, Calcium Channel Blockers, and Combinations) 2002-2009
- Figure 5-2: Total World Prescription Antihypertensive Drug Market by Type 2002-2009
- Table 5-8: Total U.S. Prescription Antihypertensive Drug Market 2002-2009
- Figure 5-3: Total U.S. Prescription Antihypertensive Drug Market 2002-2009
- Table 5-9: Total Non-U.S. Prescription Antihypertensive Drug Market 2002-2009
- Figure 5-4: Total Non-U.S. Prescription Antihypertensive Drug Market 2002-2009
- Table 5-10: Hypertensive Drugs in Development
- Table 5-11: Global Prescription Antihypertensive Drug Revenues and Market Share by Leading Supplier 2004
- Figure 5-6: Global Prescription Antihypertensive Drug Market Share by Leading Supplier 2004
chapter six: Prescription Antiarrhythmic Drugs
- Table 6-1:Currently Marketed Antiarrhythmic Drugs
- Table 6-2: World Market for Prescription Antiarrhythmic Drugs 2002-2009
- Figure 6-1: Total World Prescription Antiarrhythmic Drug Market 2002-2009
- Table 6-3: U.S. Market for Prescription Antiarrhythmic Drugs 2002-2009
- Figure 6-2: Total U.S. Prescription Antiarrhythmic Drug Market 2002-2009
- Table 6-4: Total Non-U.S. Prescription Antiarrhythmic Drug Market 2002-2009
- Figure 6-3: Total Non-U.S. Prescription Antiarrhythmic Drug Market 2002-2009
- Table 6-5: Antiarrhythmic Drugs in Development
- Table 6-6: Global Prescription Antiarrhythmic Drugs Revenues and Market Share by Leading Supplier 2004
- Figure 6-3: Global Prescription Antiarrhythmic Drug Market Share by Leading Supplier 2004
chapter seven:Prescription Vasodilator and Peripheral Vasodilator Drugs
- Table 7-1: Currently Marketed Vasodilator and Peripheral Vasodilator Drugs
- Table 7-2: World Market for Vasodilator and Peripheral Vasodilator Drugs 2002-2009
- Figure 7-1: World Market for Vasodilator and Peripheral Vasodilator Drugs 2002-2009
- Table 7-3: Total U.S. Vasodilator and Peripheral Vasodilator Drugs Market 2002-2009
- Figure 7-2: Total U.S. Vasodilator and Peripheral Vasodilator Drugs Market 2002-2009
- Table 7-4: Total Non-U.S. Vasodilator and Peripheral Vasodilator Drugs Market 2002-2009
- Figure 7-3: Total Non-U.S. Vasodilator and Peripheral Vasodilator Drugs Market 2002-2009
- Table 7-5: Vasodilator and Peripheral Vasodilator Drugs in Development
- Table 7-6: Global Vasodilator and Peripheral Vasodilator Drug Revenues and Market Share by Leading Supplier 2004
- Figure 7-4: Global Vasodilator and Peripheral Vasodilator Drug Market Share by Leading Supplier 2004
chapter eight: Prescription Antihyperlipidemic Drugs
- Table 8-1: Currently Marketed Antihyperlipidemic Drugs
- Table 8-2: World Market for Antihyperlipidemic Drugs 2002-2009
- Figure 8-1: World Prescription Antihyperlipidemic Drugs Market 2002-2009
- Table 8-3: U.S. Market for Prescription Antihyperlipidemic Drugs 2002-2009
- Figure 8-2: U.S. Prescription Antihyperlipidemic Drugs Market 2002-2009
- Table 8-4: Non-U.S. Market for Prescription Antihyperlipidemic Drugs 2002-2009
- Figure 8-3: Total Non-U.S. Prescription Antihyperlipidemic Drugs Market 2002-2009
- Table 8-4:Antihyperlipidemic Drugs in Development
- Table 8-5: Global Prescription Antihyperlipidemic Drug Revenues and Market Share by Leading Supplier 2004
- Figure 8-4: Global Prescription Antihyperlipidemic Drug Market Share by Leading Supplier 2004
chapter nine: Prescription Blood Modifiers
- Table 9-1: Currently Marketed Anticoagulant Drugs
- Table 9-2: Currently Marketed Antiplatelet Drugs
- Table 9-3: Currently Marketed Thrombolytic Drugs
- Table 9-4: World Market for Prescription Blood Modifier Drugs 2002-2009
- Figure 9-1: Total World Prescription Blood Modifier Drug Market 2002-2009
- Table 9-5: U.S. Prescription Blood Modifier Drug Market 2002-2009
- Figure 9-2: U.S. Prescription Blood Modifier Drug Market 2002-2009
- Table 9-6: Non-U.S. Prescription Blood Modifier Drug Market 2002-2009
- Figure 9-3: Non-U.S. Prescription Blood Modifier Drug Market 2002-2009
- Table 9-7: Global Market for Prescription Blood Modifier Drugs by Type (Anticoagulants, Antiplatelets, Thrombolytics) 2002-2009
- Figure 9-4: The Global Market for Prescription Blood Modifier Drugs Revenues by Type 2002-2009
- Table 9-8: Blood Modifier Drugs in Development
- Table 9-9: Global Prescription Blood Modifier Revenues and Market Share by Leading Supplier 2004
- Figure 9-5: Global Prescription Blood Modifier Drug Market Share by Leading Supplier 2004
chapter ten: Prescription Diuretic Drugs
- Table 10-1: Currently Marketed Diurectic Drugs
- Table 10-2: World Market for Prescription Diuretic Drugs 2002-2009
- Figure 10-1: World Market for Prescription Diuretic Drugs 2002-2009
- Table 10-3: U.S. Prescription Diuretic Drugs Market 2002-2009
- Figure10-2: U.S. Prescription Diuretic Drugs Market 2002-2009
- Table10-4: Non-U.S. Prescription Diuretic Drugs Market 2002-2009
- Figure 10-3: Non-U.S. Prescription Diuretic Drugs Market 2002-2009
- Table 10-5: Diuretic Drugs in Development
- Table 10-6: Global Prescription Diuretic Drug Revenues and Market Share by Leading Supplier 2004
- Figure 10-4: Total Global Market for Prescription Diuretic Drugs, Market Share by Leading Supplier 2004
chapter eleven: Prescription Other Cardiovascular Drugs
- Table 11-1: Currently Marketed Other Cardiovascular Drugs
- Table 11-2: World Market for Other Cardiovascular Drugs 2002-2009
- Figure 11-1: World Market for Other Cardiovascular Drugs 2002-2009
- Table 11-3: U.S. Market for Other Cardiovascular Drugs 2002-2009
- Figure 11-2: U.S. Market for Other Cardiovascular Drugs 2002-2009
- Table 11-4: Non-U.S. Market for Other Cardiovascular Drugs 2002-2009
- Figure 11-3: Non-U.S. Market for Other Cardiovascular Drugs 2002-2009
- Table 11-5: Other Cardiovascular Drugs in Development
- Table 11-6: World Market for Other Cardiovascular Drugs Revenues and Market Share by Leading Supplier 2004
- Figure 11-4: Total World Market for Other Cardiovascular Drugs Market Share by Leading Supplier 2004
Chapter twelve: World Market Summary
- Table 12-1: Total World Market for Prescription Cardiovascular Drugs 2002-2009
- Table 12-2: World Market for Prescription Cardiovascular Drugs by Product Segment 2002-2009
- Figure 12-3: World Prescription Cardiovascular Drug Market by Product Segment 2002-2009
- Figure 12-4: The World Market for Prescription Cardiovascular Drugs Market Share by Product Segment 2004
- Table 12-3: World Market for Prescription Cardiovascular Drugs Revenues and Segments of Participation by Major Areas of Participation 2004
Chapter thirteen: Corporate Profiles
Appendix A: Selected Emerging Cardiovascular Company Briefs
Appendix B: Company Directory
